The US National Institute of Allergy and Infectious Diseases (NIAID) will spend up to US$70 million on seven new vaccine adjuvant projects.
The lowdown: Only three vaccine adjuvants have been approved by the US Food and Drug Administration for use in human vaccines: alum, a mixture of aluminium salts that has been used in vaccines since the 1920s; GlaxoSmithKline's AS04, a combination of alum and an immune-stimulating lipid that is used in vaccines against human papilloma virus and hepatitis B virus; and GlaxoSmithKline's AS03, an oil-in-water adjuvant that was used in an H5N1 vaccine. New adjuvants, the NIAID hopes, could help to improve current vaccines, extend the vaccine supply or enhance vaccine efficacy in immune-compromised individuals. To this end, the NIAID is funding seven new adjuvant-discovery contracts, aiming in particular to find adjuvants that can activate the adaptive immune system.
This funding will enable academic and industry researchers to: use experimental and computer-based approaches to screen more than a million molecules to identify candidates that trigger adaptive immune responses; determine how the most promising adjuvant candidates work; make structural changes to candidate molecules to improve their safety and efficacy profiles; and test vaccines that have been formulated with optimized adjuvant candidates for safety and efficacy in animals.
Rights and permissions
About this article
Cite this article
Mullard, A. NIAID amps up vaccine adjuvant work. Nat Rev Drug Discov 13, 803 (2014). https://doi.org/10.1038/nrd4485
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4485